BLFS
BioLife Solutions, Inc.NASDAQHealthcare$19.51+1.14%ClosedMarket Cap: $942.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.51
P/S
9.79
EV/EBITDA
-115.61
DCF Value
$-4.69
FCF Yield
1.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.6%
Operating Margin
-12.6%
Net Margin
-12.6%
ROE
-3.4%
ROA
-6.3%
ROIC
-3.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $18.8M | 67.5% | $5.8M | $3.5M | $0.08 | — |
| FY 2025 | $96.2M | 64.6% | $-12.1M | $-12.1M | $-0.25 | — |
| Q3 2025 | $28.1M | 61.4% | $-89.0K | $621.0K | $0.01 | — |
| Q2 2025 | $25.4M | 64.6% | $-16.6M | $-15.8M | $-0.33 | — |
| Q1 2025 | $23.9M | 65.9% | $-1.2M | $-448.0K | $-0.01 | — |
| Q4 2024 | $-3.4M | -241.6% | $1.4M | $12.5M | $0.26 | — |
| FY 2024 | $82.3M | 65.3% | $-7.1M | $-20.2M | $-0.44 | — |
| Q3 2024 | $30.6M | 71.3% | $-1.6M | $-1.7M | $-0.04 | — |
| Q2 2024 | $19.7M | 67.0% | $-3.7M | $-20.7M | $-0.45 | — |
| Q1 2024 | $18.4M | 66.4% | $-3.3M | $-10.2M | $-0.22 | — |
| Q4 2023 | $17.4M | 52.1% | $-7.5M | $-13.4M | $-0.30 | — |
| FY 2023 | $75.9M | 61.6% | $-23.4M | $-66.4M | $-1.52 | — |